Headquartered in New Haven, CT,Achillion applies expertise in biology and structure-guided design and a deep understanding of patient and clinician needs to develop innovative treatment solutions aimed at improving the lives of patients. More...
Hepatitis C is a worldwide epidemic affecting more than 150 million individuals. Click to learn more about this disease.
No upcoming events at this time.
Achillion Shows Potential for "Best-in-Disease" HCV Regimen - 100% SVR4 Following a Dual 6-Week ACH-3102-Based Regimen and Separately a 4.8 Log10 Reduction With ACH-3422
Achillion to Present at Two Upcoming Investor Conferences